Canan Koksal

Canan Koksal

Auto-generated profile, based on publicly available information

Canan Koksal

Department of Medical Physics, Institute of Oncology, Istanbul University, 34093 Istanbul, Türkiye

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Medical Dosimetry
Verified
Journal Article
Closed access
CKCanan Koksal
Canan Koksal
NKNazmiye Donmez Kesen
Nazmiye Donmez Kesen
MOMurat Okutan
Murat Okutan
SKSule Karaman
Sule Karaman
NSNergiz Dagoglu Sakin
Nergiz Dagoglu Sakin
HBHatice Bilge
Hatice Bilge

1 January 2018
Verified
Journal Article
Closed access
CKCanan Koksal
Canan Koksal
UAUgur Akbas
Ugur Akbas
NKNazmiye Donmez Kesen
Nazmiye Donmez Kesen
MOMURAT OKUTAN
MURAT OKUTAN
HBHatice Bilge
Hatice Bilge
GKGonul Kemikler
Gonul Kemikler

25 August 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
KIKamuran Ibis
Kamuran Ibis
CICan Ilgin
Can Ilgin
LSLeyla Suncak
Leyla Suncak
CACanan Koksal Akbas
Canan Koksal Akbas
DBDeniz Bölükbaş Bölükbaş
Deniz Bölükbaş Bölükbaş
IYInci Kizildag Yirgin
Inci Kizildag Yirgin
Objective: To investigate the survival prediction probability of the nomogram from retro-EMBRACE and the T-score in patients with locally advanced cervical cancer (LACC). Materials and Methods: A total of 204 patients with LACC who underwent curative chemoradiotherapy and brachytherapy (BT) between 2010 and 2021 were included in our single-center retrospective study. Clinical records, examinations, and magnetic resonance images (MRI) before and after external beam radiotherapy (EBRT) were retrospectively reviewed to obtain information on age, tumor size, parametrial involvement, ureteral involvement, bladder invasion, uterine involvement, high-risk clinical target volume at the first brachytherapy application, lymph node involvement, vaginal involvement, recurrence, metastasis, and last follow-up. The 5-year overall survival probabilities of the patients were determined by nomogram. T-score was calculated separately at diagnosis (TSD) and brachytherapy (TSBT), and their effects on local recurrence-free survival, disease-free survival, and overall survival were analyzed. Results: The median age was 52 (29–89). The 5-year survival rate of the patients was calculated to be 90.18%. The median nomogram’s survival estimate for 60 months was 70.35% (20.9–87.1). The median TSD and TSBT were 5.5 (1–16) and 1 (0–6), respectively. According to the multivariate Cox regression models, TSD (HR = 1.203, 95% CI 1.021–1.417, p = 0.024) was significantly associated with local recurrence-free survival. Conclusions: This study demonstrated that the nomogram’s predictions for 60-month overall survival are underestimates. Prognosis can be estimated using the TSD, which can be easily obtained with a clinical examination and detailed MRI examination.

16 October 2025 in Medicina
Verified
Journal Article
Open access
PDF file
KIKamuran Ibis
Kamuran Ibis
KTKubra Ozkaya Toraman
Kubra Ozkaya Toraman
CACanan Koksal Akbas
Canan Koksal Akbas
ÖGÖZLEM GÜLER GÜNİKEN
ÖZLEM GÜLER GÜNİKEN
KKKorhan Kokce
Korhan Kokce
MAMusa Altun
Musa Altun
Background and Objectives: This study aimed to compare target volumes and organ-at-risk (OAR) doses using five different volume definitions in radiotherapy (RT) planning of patients with glioblastoma multiforme (GBM). Materials and Methods: Rigid image fusion was performed using simulation computed tomography and postoperative magnetic resonance imaging scans of 20 patients with GBM. Volumetric modulated arc therapy (VMAT) plans were generated according to three two-phase protocols—American Brain Tumor Consortium (ABTC), North Central Cancer Treatment Group/Alliance (NCCTG/Alliance), and Radiation Therapy Oncology Group/NRG (RTOG/NRG)—and two single-phase protocols—European Organisation for Research and Treatment of Cancer (EORTC) and European Society for Radiotherapy and Oncology–European Association of Neuro-Oncology (ESTRO/EANO)—each delivering a total dose of 60 Gy. OARs and dose constraints were evaluated. Statistical analysis was performed using the paired sample t-test. Results: The ESTRO/EANO volume had the smallest median PTV overall (p < 0.001). The lowest brain-PTV Dmean in the initial phase was observed in the ABTC group, followed closely by ESTRO/EANO (p < 0.001). Among boost volumes, the ABTC volume was the smallest, and the median brain-PTV Dmean was lowest in the ESTRO/EANO volume. ESTRO/EANO provided the lowest doses for contralateral and ipsilateral cochlea Dmean, brainstem D1cc, and contralateral lens Dmax. Notably, both EORTC and ESTRO/EANO plans maintained OAR doses within acceptable constraints, with ESTRO/EANO achieving the most consistently minimised exposure. Conclusions: Reduced irradiated brain volume, acceptable OAR preservation and practical applicability, the use of ESTRO-EANO and EORTC target volumes in radiotherapy of glioblastoma multiforme may provide dosimetric advantages that require further validation in clinical outcome studies.

1 August 2018 in Physica Medica
Verified
Journal Article
Closed access
UAUgur Akbas
Ugur Akbas
NKNazmiye Donmez Kesen
Nazmiye Donmez Kesen
CKCanan Koksal
Canan Koksal
HBHatice Bilge
Hatice Bilge

22 August 2023 in Radiation Physics and Chemistry
Verified
Journal Article
Closed access
CACanan Koksal Akbas
Canan Koksal Akbas
GAGokce Ucar Alveroglu
Gokce Ucar Alveroglu
LSLeyla Suncak
Leyla Suncak
SKSule Karaman
Sule Karaman
NDNergiz Dagoglu
Nergiz Dagoglu
HBHatice Bilge Becerir
Hatice Bilge Becerir